Effect of CGF on Postoperative Pain After Third Molar Surgery

The Power of Concentrated Growth Factor: A New Era in Pain Management in Third Molar Surgery

The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.

The main question it aims to answer is:

Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).

Study Overview

• Status: Completed
• Conditions: Oral Complication
• Intervention / Treatment: Other: Concentrated Growth Factor; Other: non-CGF

• Study Type: Interventional
• Enrollment (Actual): 49
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Bornova
    • Izmir, Bornova, Turkey, 35040
      • Ege University Faculty of Dentistry

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
• Patients without any systemic disease
• Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.

Exclusion Criteria:

• Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
• Having a systemic viral, fungal or bacterial infection
• Patients with acute or chronic maxillary sinusitis
• Suspected or diagnosed pregnancy and nursing mothers
• Patients with heart and vascular diseases
• Patients with liver disease, haematological disease and neoplastic disease
• Patients who have recently received anti-inflammatory therapy
• Patients with chronic medication use (antihistamines, NSAIDs, steroids and antidepressants)
• Patients predisposed to psychotic or psychopathic tendencies
• Patients with rheumatic diseases, blood diseases, diabetes mellitus
• Patients at cardiological risk of infective endocarditis
• Patients under antibiotic pressure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CGF; Participants received CGF after the operation on one side	Other: Concentrated Growth Factor; Bilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets.; Other: non-CGF; The other extraction socket is left empty for control purposes.
No Intervention: non-CGF; The other extraction socket is left empty

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery	The primary outcome measure is postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale (VAS). Patients are asked to mark the pain they felt on the scale (10 cm long line) on the (1-7) days after the operation. The end of the line indicates unbearable pain, the beginning indicates no pain.	The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).

Collaborators and Investigators

• Sponsor: Ege University
• Investigators: Principal Investigator: Mert Zeytinoğlu, Ege University

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2017
• Primary Completion (Actual): January 1, 2018
• Study Completion (Actual): June 5, 2018

Study Registration Dates

• First Submitted: March 31, 2025
• First Submitted That Met QC Criteria: April 6, 2025
• First Posted (Actual): April 9, 2025

Study Record Updates

• Last Update Posted (Actual): April 20, 2025
• Last Update Submitted That Met QC Criteria: April 16, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Pain; Third molar; VAS scale
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Postoperative Complications; Pathologic Processes; Pain, Postoperative; Molecular Mechanisms of Pharmacological Action; Mitosis Modulators; Mitogens
• Other Study ID Numbers: EGE-DHF-MZ-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No